Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Here’s What Happened

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw strong trading volume on Tuesday . 2,633,329 shares traded hands during mid-day trading, an increase of 53% from the previous session’s volume of 1,716,444 shares.The stock last traded at $27.3840 and had previously closed at $27.91.

Analyst Ratings Changes

Several research analysts recently commented on GMAB shares. Jefferies Financial Group started coverage on Genmab A/S in a research report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Guggenheim cut their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Wells Fargo & Company began coverage on Genmab A/S in a report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Finally, Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.36.

Genmab A/S Stock Performance

The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 1.23 and a beta of 0.97. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a 50 day moving average price of $27.79 and a two-hundred day moving average price of $30.29.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. On average, analysts predict that Genmab A/S Sponsored ADR will post 1.17 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Aaron Wealth Advisors LLC increased its stake in shares of Genmab A/S by 17.4% in the first quarter. Aaron Wealth Advisors LLC now owns 9,285 shares of the company’s stock valued at $249,000 after buying an additional 1,375 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Genmab A/S by 36.3% in the first quarter. SG Americas Securities LLC now owns 8,887 shares of the company’s stock valued at $238,000 after buying an additional 2,365 shares in the last quarter. Rockefeller Capital Management L.P. increased its position in Genmab A/S by 472.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 12,572 shares of the company’s stock worth $387,000 after purchasing an additional 10,376 shares during the period. Corient Private Wealth LLC increased its position in Genmab A/S by 10.9% in the fourth quarter. Corient Private Wealth LLC now owns 17,469 shares of the company’s stock worth $538,000 after purchasing an additional 1,724 shares during the period. Finally, MidFirst Bank acquired a new stake in Genmab A/S in the fourth quarter worth about $56,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.